This is the authors' abstract. We don't add key points for this paper.
Background: The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented. However, ICIs can enhance immune responses and trigger autoimmune-related diseases by blocking PD-1 or PD-L1. The worst prognosis is observed in paraneoplastic neurological syndromes (PNS). This study aimed to evaluate the clinical characteristics of PD-1/PD-L1 inhibitor-related PNS and the prognostic impact of antibody subtypes, with the goal of enabling pre-treatment risk warning. Methods: This was a retrospective descriptive study involving 224 patients with PD-1/PD-L1 inhibitor-related PNS from May 2015 to May 2025, including 8 patients who presented at our hospital and 216 patients reported in the literature. According to the July 2021 international consensus diagnostic framework for PNS, patients were stratified into risk-antibody (high-, intermediate-, and low-risk), unknown-risk antibody, and antibody-negative groups. Clinical features, primary tumor type, ICI regimen, autoantibody profile, treatments, and outcomes were analyzed. Risk-antibody subtypes were further explored. Results: There were 112 patients in the risk-antibody group (87 high-risk, 20 intermediate-risk, and 5 low-risk), 51 in the unknown-risk antibody group, and 61 in the antibody-negative group. The risk-antibody group showed a higher incidence of limbic encephalitis, subacute cerebellar degeneration, and subacute sensory neuronopathy. The prognosis was worse in the risk-antibody group, with a mortality rate of 29%, significantly higher than 17% in the unknown-risk group and 10% in the antibody-negative group (P = 0.012). Anti-Hu-positive patients were mainly diagnosed with limbic encephalitis, encephalomyelitis, and subacute cerebellar degeneration, with a mortality rate of 23%. Anti-Ma-positive patients primarily presented with encephalomyelitis, limbic encephalitis, and subacute cerebellar degeneration, with a mortality rate of 35%. Anti-Yo-positive patients were mainly associated with subacute cerebellar degeneration, with a mortality rate of 25%. The mortality rate among Anti-amphiphysin-positive patients was 33%. In contrast, 71% of Anti-NMDAR-positive patients had favorable outcomes. Conclusion: Among patients with PD-1/PD-L1 inhibitor-related PNS, those with risk-antibody positivity had worse prognoses, while patients with unknown-risk antibodies had outcomes similar to those with antibody negativity, suggesting that unknown-risk antibodies are not directly pathogenic or may elicit weaker immune responses. Pre-treatment screening for PNS-related antibodies is recommended, as it may facilitate early warning, identify high-risk patients, and help prevent autoimmune-related diseases caused by excessive immune modulation. After disease onset, efficient immunomodulatory treatment tailored to antibody subtypes may improve outcomes in risk-antibody-positive patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: